Helmut Zodl: Yes. Thank you, Drew. I think so when we look at the overall margin expansion in the 50 basis points to 100 basis points, there is a number of drivers in there So clearly, volume is a driver, VCP, so we have a cost productivity, improvement in material cost, improvement in logistics cost, and also price is key drivers. So those are really, I would say, those key elements that are driving them with the positive improvement on the margin side. If you look at the headwinds against that, we’re still seeing material costs elevated. So especially material cost that is sitting on our balance sheet, in our inventory currently. And we also continue to invest into the business, both for our growth, but also what we are putting innovation investment in R&D into the business.
So these are really the offsetting element. So both of those elements together are really driving our 50 basis point to 100 basis point margin expansion and we’re very focused on what is really in our control, which is price, VCP and obviously volume execution. That’s really how we look at the margin expansion for 2023. If I give you a little bit more color, Drew, on the four segments, obviously, as you’ve seen in the fourth quarter, the Imaging segment, very strong with its growth. We expect that growth, as we work through our backlog, continue especially for the first half. So there’s going to be more growth on the imaging side. But also all our other three segments, Ultrasound, PCS and PDx, we expect to grow in that range as we have laid out the 5% to 7% as we go forward.
So it’s a very good balance as we go into the New Year.
Operator: Our next question comes from Ed Ridley-Day with Redburn. Your line is open.
Peter Arduini: Good morning.
Ed Ridley-Day: Good morning. Thank you very much, and I’d add my congratulations on your successful spin and your results. And first question for me would be actually around your molecular imaging business, this continues to drive growth in the wider imaging business. Could you help us better quantify the benefits you see there, particularly what percent of your imaging business does this represent roughly? And also in pharmaceutical diagnostics, you have provided the market breakdown between contrast and molecular. But what percent of pharmaceutical diagnostics is radio pharmaceuticals? It’s a great opportunity. So it’d be great to have any color you can give on that? And just a quick follow-up on pricing. Could you give us an idea of the price €“ rough price increase you hope to push through for this year? Thank you.
Peter Arduini: Thanks, Ed, for the questions, Yes, I’ll start maybe a little bit with MI and frame it up, and then maybe, Helmut, you can comment a little bit on price. I would start first with saying, yes, I think one of the really interesting things that we’re excited about strategically is we’re the only company out there that actually makes the fuels for molecular imaging as well as has the devices that capture to create the images themselves. Why that’s important is this rise of different technologies out there called theranostics, this combination of a therapy and a diagnostic together and how you tune the device to the agent whether it be in the neurosciences area such as Parkinson’s or amyloid beta plaque imaging or other parts of the body.